The results of the study showed that both SHR6390 and pyrotinib inhibited the tumor proliferation of HER2+/HR+ cell lines (pyrotinib IC50 0.8 ± 0.1 μg/ml in EFM-192A, 4.6 ± 0.2 μg/ml in BT474; SHR6390 IC50 3 ± 0.2 μg/ml in EFM-192A, 6.4 ± 0.2 μg/ml in BT474). The gene discussed is ERBB2; the disease is neoplasm.